NCT03679624 - Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 30, 2020

Primary Completion Date

September 15, 2020

Study Completion Date

October 13, 2020

Conditions

Waldenstrom MacroglobulinemiaWaldenstrom's DiseaseWaldenström; HypergammaglobulinemiaWaldenstrom's Macroglobulinemia RecurrentWaldenstrom's Macroglobulinemia of Lymph NodesWaldenstrom's Macroglobulinaemia, Without Mention of RemissionWaldenstrom's Macroglobulinemia Refractory

Interventions

DRUG

Ibrutinib

Ibrutinib, 420mg orally, once daily

DRUG

Daratumumab

Daratumumab, 16 mg/kg intravenously, weekly for 8 weeks, bi weekly for 16 weeks, then monthly for up to 19 months.

Trial Locations (1)

10065

Weill Cornell Medicine, New York